OPINION Neutropenia in primary immunodeficiency
INTRODUCTION
The primary immunodeficiency diseases (PIDDs) include more than 150 different conditions [1 && ]. In the past 2 years, advances in this field have occurred in both myeloid and lymphoid immunodeficiencies. This review will address recent developments in these areas, with a primary focus on entities that lead to neutropenia as an isolated finding or in the context of other immune defects (Table 1) [ [50] [51] [52] [53] [54] [55] [56] [57] [58] , excluding marrow disorders presenting as pancytopenia and disorders only described in single patients or kindreds. Treatment of neutropenia in the setting of PIDD will also be discussed. and venous angiectasia. In the past 2 years, extensive work has been done to delineate both the pathophysiology and the range of phenotypes of this syndrome.
The first patients described with G6PC3 deficiency had an absence of mature neutrophils in the marrow, consistent with early apoptosis. In 2010, McDermott et al. [9] published a variant form of the disease showing myelokathexis. The two patients reported in this article were homozygous for a missense mutation at nucleotide 778 of G6PC3, coding for p.G260R. McDermott et al. reported decreased oxidase activity in their two patients, which was not identified in the original G6PC3deficient cohort. Although the cohort of Boztug et al. [7] did include two patients with G260R, neither of these patients' bone marrows was assessed morphologically. Because of the finding of myelokathexis, McDermott et al. [9] examined the expression of CXCR4, the protein that is absent or mutated in warts, hypogammaglobulinemia, infection, and myelokathexis (WHIM) syndrome, in their patients and in G6pc3-knockout mice, finding it to be elevated in both cases. Treatment of the patients with granulocyte-colony stimulating factor (G-CSF) led to a decrease in CXCR4 expression along with an increase in absolute neutrophil count (ANC). Further tying the increased expression of CXCR4 to the patients' neutropenia, plerixafor, a specific CXCR4 antagonist, mobilized neutrophils into the circulation of G6pc3-knockout mice.
Neutropenia with G6PC3 mutations was further described in 2011 by a British-Israeli team [61 & ]. All four reported patients were members of a single kindred of Palestinian citizens of Israel and shared the same missense mutation as the first family reported by Boztug et al. [7] , c.758G>A leading to p.R253H. Three of the patients in this report were in their third decade, all older than the patients of Boztug et al. [7] . Consequently, Banka et al. [61 & ] describe their patients as representing the adult phenotype of SCN4. This phenotype includes venous varicosities and stasis ulcers, growth delay and small adult size, developmental delay or learning disabilities, and delayed sexual maturation in two of the three adult patients. The extent to which these findings represent the true adult phenotype of G6PC3 mutation versus coinherited phenotypes in this highly consanguineous family is not clear, although venous varicosities and stasis ulcers could be related to the venous ectasia described by Boztug et al. The description of this phenotype may have important clinical implications for patients with G6PC3 mutations, because stasis ulcers would represent a substantial clinical problem in the setting of neutropenia.
Although not commented upon by the authors, the ANCs of the Palestinian patients reported by Banka et al. [61 & ] appear to be higher than those of the Aramean patients with the same mutation reported by Boztug et al. [7] . In the earlier paper, two out of five patients never had ANCs above 100 cells/ml, whereas the lowest ANC reported by the Israeli-British team was 200 cells/ml. The youngest patient was able to mount an ANC of 7700 cells/ml, although under what clinical circumstances is not clear. Banka et al. do not mention the extent to which their patients were treated with G-CSF, and if they do have higher neutrophil counts than the patients of Boztug et al. they may not be cytokine-dependent. This difference may be explained by other genomic factors, or it could represent the variability of the newly described disease.
Gatti et al. [62] presented a case report of the first South American patient with G6PC3 deficiency in 2011. The mutation was a two base pair deletion leading to a frameshift. The child had lived 10 years without diagnosis or treatment. Between infections, the ANC could rise above 1000 cells/ml. The marrow showed a lack of mature neutrophils and was otherwise described as nonspecific.
Despite an apparently benign bone marrow examination, the patient had neutropenia below 200 cells/ml, anemia with reticulocytopenia, and thrombocytopenia. The two patients of McDermott et al. [9] were said to have iron deficiency anemia. In the report of Banka et al. [61 & ], all four patients are said to be anemic, but reticulocyte counts or further evaluation are not mentioned, and patient number 1 appears to be persistently thrombocytopenic. Boztug et al. [7] mention mild thrombocytopenia in one of their patients, but otherwise do not describe findings in red cells or platelets in their initial report. The contribution of either GFI1 AD G-CSF [10] Not reported
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Yes [14] Cyclic neutropenia ELANE AD G-CSF [15] Not increased [16] No X-linked neutropenia WASP XR G-CSF [17] Increased [18] No WASp is constitutively active [19] . All reported mutations in GTPase binding domain [20] IRAK-4 deficiency Ten of these 16 had intermittent thrombocytopenia. The most common nonhematologic manifestation was venous ectasia, present in 14 of the 16 patients. Four patients had homozygous frameshift mutations, although there was no comment on their clinical course being better or worse than average. Fifteen of the 16 patients were maintained on G-CSF, with doses averaging 3.3 mg/kg/day, and ranging from 0.7 to 14 mg/kg/ day. Twelve of the 15 used G-CSF less than once per day. In almost three centuries of cumulative follow-up, no patient developed leukemia, and this was found to be statistically different from an SCN cohort of 374 patients. No patient had myelokathexis. In some patients, the authors noted an SCN4 phenotype without mutations in the coding region of G6PC3, suggesting that other genes may be involved in SCN4.
Three recent articles have investigated the pathophysiology of the G6PC3 deficiency. Using a knockout mouse model [63] , Jun et al. [64] showed that glucose transport out of the ER is deficient in neutrophils of G6pc3À/À mice and G6PC3À/À humans. Biochemical results of this deficiency included decreased glucose-6-phosphate in neutrophil cytoplasm, decreased lactate, and decreased ATP. In the murine model, neutrophils had decreased levels of the phagocyte oxidase proteins and inhibited oxidative burst, chemotaxis, and phagocytosis. In this respect, the knockout mice differ from the first kindred presented by Boztug et al. [7] , who were homozygous for a missense mutation and had apparently normal neutrophil function. Recently, Jun et al. [65 
POIKILODERMA WITH NEUTROPENIA
In 2010, an Italian family with Clericuzio-type poikiloderma with neutropenia was found to have a mutation in C16orf57 [67] . At that time, the gene's function was unknown. In 2012, Colombo et al. [68 & ] reported on two novel C16orf57 mutations. Further work in silico led the authors to hypothesize that C16orf57 functions in RNA processing. If this hypothesis is correct, it could provide a pathophysiologic basis for the clinical overlap of poikiloderma with neutropenia, with dyskeratosis congenita with normal telomere length, and with Rothmund-Thomson syndrome [69] .
NEUTROPENIA IN DISORDERS OF CXCL12/CXCR4 SIGNALING
The CXCR4 receptor is hyperfunctional in WHIM syndrome [70] . Based on the understanding of the molecular etiology of this disease as a gain-offunction mutation in CXCR4 [71] , McDermott et al. [72 & ] demonstrated that the CXCR4 antagonist plerixafor could counteract this hyperfunctionality. In 2011, the same authors [49 && ] and a separate group [48 && ] showed that plerixafor could be used to increase neutrophil, lymphocyte, and monocyte counts in patients with WHIM syndrome. Both studies were dose escalation studies, showing an effective dose well below the dose approved by the US Food and Drug Administration for mobilizing peripheral blood hematopoietic stem cells, 0.24 mg/kg. In their report, the group from the National Institute of Allergy and Infectious Diseases discuss the potential for unintended consequences of chronic complete blockage of CXCR4, noting the knockout mice to be nonviable. The authors claim to have only partially blocked CXCR4, estimating that at the lowest dose only about 30% of CXCR4 receptors were blocked. The data upon which this estimate is based are not presented. For this reason, and because the appropriate dose and schedule of plerixafor in WHIM syndrome have not been determined, G-CSF remains the treatment of choice [73] .
In 2012, Liu et al. [74 & ] presented the first case of WHIM syndrome caused by a point mutation in CXCR4, c.1027G->A, coding for p.343E->K. All previous reports of WHIM syndrome due to CXCR4 mutations had been of truncating mutations. As is the case for truncated proteins, McDermott et al. found the missense mutation to cause CXCR4 to be hyperfunctional.
A potential second immunodeficiency involving CXCR4 and CXCL12 was identified in 2011 [75 & ]. The reported patients had neutropenia, hypogammaglobulinemia, and recalcitrant warts, but did not have myelokathexis. Both patients had B-cell and natural killer cell lymphopenia, which is not typically associated with WHIM syndrome. Furthermore, no mutations in the CXCR4 gene were identified. The patients' lymphocytes had reduced internalization of CXCR4 when stimulated with CXCL12, a finding which the authors had previously demonstrated in patients with WHIM syndrome [76] .
NEUTROPENIA IN COMBINED IMMUNODEFICIENCY
In addition to the primary neutropenic immunodeficiencies, neutropenia can be found as a feature of what are primarily thought of as lymphoid immune deficiencies, including several subtypes of combined immunodeficiency (Table 1) .
Recent work has shown a predisposition to neutropenia among children with adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID). This was fist identified in a trial of gene therapy [77] , wherein two out of 10 patients had prolonged neutropenia after receiving 4 mg/kg of busulfan, less than half of the myeloablative dose [78] . A previous observation reported prolonged pancytopenia after a similar low dose of busulfan in a single patient [79] . Complicating the interpretation of this severe adverse event was a finding of a minority population of cells with trisomy 8 in marrow of the patient stored before gene therapy.
Our recent findings in a cohort of 13 patients with ADA-SCID further describe neutropenia in this condition [29] . Although none of the patients were profoundly neutropenic at the time of description, all of the patients had morphologic abnormalities of myeloid cells in the peripheral blood (Fig. 1) , and of the six whose marrow was studied, all were found to have cytologic dysplasia. As was seen in two of the patients of Aiuti et al. [77] , we observed prolonged neutropenia after low-dose busulfan given as conditioning prior to gene therapy for ADA-SCID. All three of the patients who received busulfan ultimately were treated with G-CSF in order to achieve a sustained ANC greater than 500 cells/ml. Additional findings included susceptibility to drug-induced neutropenia and an inverse correlation between ANC and deoxyadenosine metabolite percentage, a marker of metabolic burden of disease in ADA-SCID, at diagnosis.
Although these reports raise the suspicion of neutropenia as a feature of ADA-SCID, it is unclear whether this finding is a genuine manifestation of ADA deficiency, or whether it could be fully explained as an exaggerated response to myelotoxins, rather than an inherent myeloid abnormality. On the basis of our more recent findings, it can be argued that neutropenia is in fact a primary manifestation of ADA deficiency. We have made preliminary observations in two patients who became mixed chimeras after either allogeneic hematopoietic cell transplantation (HCT) or gene therapy for ADA-SCID [80] . In both cases, withdrawal of pegylated adenosine deaminase (PEG-ADA) months to years after cellular therapy led to an increase in the percentage of ADA-expressing lymphocytes. PEG-ADA withdrawal was accompanied by an expected increase and then fall of deoxyadenosine metabolites, during which neutropenia was observed. As metabolic control was regained with selection of ADA-expressing cells, the neutropenia improved. The patient who had had allogeneic HCT had 89% T-cell chimerism prior to PEG-ADA withdrawal. He had a transient neutropenia, whereas the gene therapy patient, who had 1% marking prior to PEG-ADA withdrawal, required prolonged administration of G-CSF before being able to maintain an ANC above 500 cells/ml. Before discontinuing the drug, the second patient used G-CSF as infrequently as once every 14 days.
Two groups described a new molecular etiology of combined immunodeficiency in April of 2012 [35 & ,36 & ]. The patients studied by Abdollahpour et al. [35 & ] were three members of a single Iranian family with stop mutations due to a single nucleotide substitution in exon 7 of STK4, also known as MST1, a gene whose product has antiapoptotic activity. In addition to deficiencies of B and T cell numbers, all three patients had neutropenia. Infections were both bacterial and viral. T cells and neutrophils showed increased apoptosis. Although these patients presented between ages 2 and 10, and were able to make specific antibodies against tetanus and diphtheria toxoids, two other members of the kindred died from sepsis in infancy.
Nehme et al.
[36 & ] presented four Turkish patients from two consanguineous marriages with mutations in STK4. All patients had viral and bacterial infections, neutropenia, and autoimmunity. T-cell function was also impaired. Patients had elevated levels of IgG and IgA and made antibodies to polio, but not to tetanus or diphtheria toxoids, or to Haemophilus influenzae or Streptococcus pneumoniae. The authors characterized the syndrome as combined immunodeficiency rather than SCID. All four patients had truncating mutations of STK4. Additional findings included a decreased amount of IL7Ra, a protein absent in a minority of autosomal recessive SCID patients. Two patients died after alternative donor HCT, and one was cured by the procedure.
TREATMENT OF NEUTROPENIA IN PRIMARY IMMUNODEFICIENCY DISEASE
Febrile neutropenia is a medical emergency in all cases. Although outpatient treatment with oral antibiotics has been advocated for low-risk patients expected to recover their white counts after cancer chemotherapy [81] , the data for such an approach do not exist for neutropenia in PIDD, and this strategy cannot be recommended. Appropriate management consists of empiric broad-spectrum antibiotics administered in an inpatient setting. As in postchemotherapy neutropenia, localizing signs and symptoms may be lacking in neutropenic patients with PIDD. However, unlike the case with postchemotherapy neutropenia, patients with PIDD and neutropenia are often able to increase their ANC in the face of an infectious challenge. Although this may make the outcomes of febrile neutropenia in PIDD less severe than in the postchemotherapy setting, data for this hypothesis are lacking. Furthermore, patients with postchemotherapy neutropenia can be expected to recover their counts in a few days, whereas patients with neutropenic PIDD will not. The original data supporting empiric antibiotics for febrile neutropenia come from the postchemotherapy setting [82] , and, in the absence of data specific to PIDD, it seems appropriate to extrapolate from these data in making treatment decisions. Beyond the acute setting, treatment of neutropenia in PIDD depends on the underlying disorder, the overall health of the patient, and the goals of the patient and family. In the precytokine era, patients with irreversible neutropenia who were not cured by HCT could be given prophylactic antibiotics. Although this approach is still advocated by some experts [13] , it is not universally recommended [83 && ], and other authors cite G-CSF as the treatment of choice for neutropenia in PIDD [45, 53] . In the case of autoimmune neutropenia in humoral or combined immunodeficiencies, consideration can be given to corticosteroid treatment, although this must be done with caution in patients with PIDD and severe neutropenia. Alternative treatments include immunoglobulin replacement, G-CSF [84], and rituximab or alemtuzumab [46] .
For the primary neutropenic disorders, G-CSF is the treatment of choice in the absence of curative HCT [83 && ]. This treatment has reduced infectious morbidity [85] and mortality [86] . Although only 5% of patients with SCN have no response to G-CSF [87] , the amount of cytokine needed varies greatly from less than 5 to 120 mg/kg/day. Those patients who do not respond to 120 mg/kg/day of G-CSF are unlikely to respond to higher doses [88] and are appropriate candidates for HCT. Included among this group are patients with a constitutive extracellular G-CSFR mutation [14, 89, 90] , who are absolutely refractory to G-CSF. Patients who require more than 8 mg/kg/day of G-CSF have an increased risk for leukemic transformation [86] .
The use of pegfilgrastim instead of filgrastim is theoretically attractive, and has been tried in isolated cases [91] [92] [93] [94] , but has not been routinely accepted, and may in fact lead to an increase in adverse events [95, 96] . One obstacle to the use of this agent in the United States is the packaging of the commercially available product in a syringe prefilled with the adult dose of 6 mg. This would require either intentional overdosing or the cumbersome prospect of pharmacist re-packaging of the medicine if pegfilgrastim were used for children.
The experience of our group with neutropenia in ADA-SCID has been more variable. G-CSF is typically only needed after myelotoxic challenges, such as chemotherapy or myelotoxic drugs, and then only for a few weeks [29] . Antineutrophil antibodies have been found in several patients with ADA-SCID; however, the usual caveats of serologic diagnosis in patients on immunoglobulin replacement, as well as the known concerns about the poor specificity of the antineutrophil antibody assays, apply. There is no reported experience of the use of immunosuppression in this situation. The utility of PEG-ADA to treat the neutropenia of ADA-SCID is not clear.
For most PIDDs, the only curative treatment is allogeneic HCT [97, 98] . Although this procedure is clearly indicated in SCID [99 && ], with the possible exception of ADA-SCID without a matched related donor [100] , it is more selectively applied in other PIDDs (Table 1) . PIDDs with neutropenia in which HCT is generally considered to potentially have a favorable risk-benefit ratio include, in addition to SCID, X-linked hyper-IgM syndrome (CD40L deficiency), Chediak-Higashi syndrome, Griscelli syndrome, severe congenital neutropenia, and cyclic neutropenia [97] .
Finally, genetically modified autologous HCT has been used as an investigational modality in several PIDDs [101] [102] [103] [104] [105] [106] [107] , with notable successes in SCID, chronic granulomatous disease, and Wiskott-Aldrich syndrome. Gene therapy remains a potentially useful modality for PIDDs with neutropenia, but is still at the preclinical stage for most of them. Even in those disorders in which gene therapy has been carried out, its application must be judicious, given the potential for life-threatening or fatal adverse events [108] [109] [110] (and, press release from Hannover Medical School, http://www.asgct.org/ UserFiles/file/Genetherapy_WAS_final_english.pdf, accessed 1 August 2012).
CONCLUSION
Neutropenia is a feature of several myeloid and lymphoid PIDDs. The many different pathophysiologies represented by the PIDDs lend themselves to, and in fact necessitate, a more diversified and nuanced treatment approach than the standard used for febrile neutropenia after cancer chemotherapy. Additional clinical observations and investigations into both the pathophysiology and the management of neutropenia in the different PIDDs, as an isolated complication and in the context of the underlying disease, are required and can be expected. Until such new data are presented, the management of neutropenia in PIDDs will require a flexible, empiric, and patient-centered approach based on the use of cytokines and HCT with consideration of antibiotic prophylaxis and gene therapy in the appropriate settings.
48.

&&
Dale DC, Bolyard AA, Kelley ML, et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood 2011; 118:4963-4966. This is one of two studies published simultaneously that demonstrate in vivo that plerixafor can increase the neutrophil, monocyte, and lymphocyte counts of patients with WHIM syndrome. This may ultimately lead to improved therapy for the disease.
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